Literature DB >> 33681288

Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis.

Lu Yin1, Liuzhi Zhou2, Rujun Xu1.   

Abstract

We aimed to explore the tumor mutational burden (TMB) and immune infiltration in HCC and investigate new biomarkers for immunotherapy. Transcriptome and gene mutation data were downloaded from the GDC portal, including 374 HCC samples and 50 matched normal samples. Furthermore, we divided the samples into high and low TMB groups, and analyzed the differential genes between them with GO, KEGG, and GSEA. Cibersort was used to assess the immune cell infiltration in the samples. Finally, univariate and multivariate Cox regression analyses were performed to identify differential genes related to TMB and immune infiltration, and a risk prediction model was constructed. We found 10 frequently mutated genes, including TP53, TTN, CTNNB1, MUC16, ALB, PCLO, MUC, APOB, RYR2, and ABCA. Pathway analysis indicated that these TMB-related differential genes were mainly enriched in PI3K-AKT. Cibersort analysis showed that memory B cells (p = 0.02), CD8+ T cells (p = 0.09), CD4+ memory activated T cells (p = 0.07), and neutrophils (p = 0.06) demonstrated a difference in immune infiltration between high and low TMB groups. On multivariate analysis, GABRA3 (p = 0.05), CECR7 (p < 0.001), TRIM16 (p = 0.003), and IL7R (p = 0.04) were associated with TMB and immune infiltration. The risk prediction model had an area under the curve (AUC) of 0.69, suggesting that patients with low risk had better survival outcomes. Our study demonstrated for the first time that CECR7, GABRA3, IL7R, and TRIM16L were associated with TMB and promoted antitumor immunity in HCC.
Copyright © 2021 Yin, Zhou and Xu.

Entities:  

Keywords:  biomarkers; hepatocellular carcinoma; immune infiltration; prognosis; tumor mutation burden

Year:  2021        PMID: 33681288      PMCID: PMC7928364          DOI: 10.3389/fmolb.2020.599142

Source DB:  PubMed          Journal:  Front Mol Biosci        ISSN: 2296-889X


  9 in total

1.  Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma.

Authors:  Qiongyue Zhang; Yan Huang; Yu Xia; Yumeng Liu; Jianhe Gan
Journal:  Clin Exp Med       Date:  2022-09-24       Impact factor: 5.057

2.  Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis.

Authors:  Changjing Huang; Chenyue Zhang; Jie Sheng; Dan Wang; Yingke Zhao; Ling Qian; Lin Xie; Zhiqiang Meng
Journal:  Front Genet       Date:  2021-11-26       Impact factor: 4.599

3.  Integrative Genomic Analyses of 1,145 Patient Samples Reveal New Biomarkers in Esophageal Squamous Cell Carcinoma.

Authors:  Binbin Zou; Dinghe Guo; Pengzhou Kong; Yanqiang Wang; Xiaolong Cheng; Yongping Cui
Journal:  Front Mol Biosci       Date:  2022-01-21

4.  A multi-omics-based investigation of the immunological and prognostic impact of necroptosis-related genes in patients with hepatocellular carcinoma.

Authors:  Hang Yang; QiNian Jiang
Journal:  J Clin Lab Anal       Date:  2022-03-15       Impact factor: 2.352

5.  Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma.

Authors:  Jun Cao; Bingbing Su; Rui Peng; Hao Tang; Daoyuan Tu; Yuhong Tang; Jie Zhou; Guoqing Jiang; Shengjie Jin; Qian Wang; Aoqing Wang; Renjie Liu; Qiangwei Deng; Chi Zhang; Dousheng Bai
Journal:  J Gastrointest Oncol       Date:  2022-08

6.  Key Genes Associated with Tumor-Infiltrating Non-regulatory CD4- and CD8-Positive T Cells in Microenvironment of Hepatocellular Carcinoma.

Authors:  Zijun Zhao; Chaonan Wang; Peishan Chu; Xin Lu
Journal:  Biochem Genet       Date:  2022-01-29       Impact factor: 2.220

7.  Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis.

Authors:  Zhi-Yong Liu; Dan-Ying Zhang; Xia-Hui Lin; Jia-Lei Sun; Weinire Abuduwaili; Guang-Cong Zhang; Ru-Chen Xu; Fu Wang; Xiang-Nan Yu; Xuan Shi; Bin Deng; Ling Dong; Shu-Qiang Weng; Ji-Min Zhu; Xi-Zhong Shen; Tao-Tao Liu
Journal:  Front Pharmacol       Date:  2022-08-22       Impact factor: 5.988

8.  Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma.

Authors:  Ritu Shrestha; Kim R Bridle; Darrell H G Crawford; Aparna Jayachandran
Journal:  Int J Med Sci       Date:  2021-04-22       Impact factor: 3.738

9.  Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden.

Authors:  Joseph W Franses; Irun Bhan; Amaya Pankaj; David T Ting; Vikram Deshpande; Kenneth Tanabe
Journal:  JCO Precis Oncol       Date:  2021-06-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.